Insider Selling: Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Sells 6,000 Shares of Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $45.49, for a total value of $272,940.00. Following the transaction, the chief financial officer now directly owns 13,040 shares of the company’s stock, valued at $593,189.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Thursday, September 10th, Thomas Patrick Kelly sold 3,000 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $47.71, for a total value of $143,130.00.

NASDAQ:DCPH opened at $44.18 on Friday. The company has a quick ratio of 12.30, a current ratio of 12.33 and a debt-to-equity ratio of 0.02. Deciphera Pharmaceuticals Inc has a 52-week low of $31.37 and a 52-week high of $71.11. The stock has a fifty day simple moving average of $46.29 and a 200-day simple moving average of $50.15.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.14. As a group, research analysts predict that Deciphera Pharmaceuticals Inc will post -5.24 EPS for the current year.

Several large investors have recently added to or reduced their stakes in DCPH. Vanguard Group Inc. raised its stake in shares of Deciphera Pharmaceuticals by 41.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,549,561 shares of the company’s stock worth $211,980,000 after buying an additional 1,034,589 shares during the last quarter. Franklin Resources Inc. raised its stake in Deciphera Pharmaceuticals by 36.4% in the 1st quarter. Franklin Resources Inc. now owns 3,237,383 shares of the company’s stock valued at $133,283,000 after purchasing an additional 864,661 shares during the last quarter. Redmile Group LLC raised its stake in Deciphera Pharmaceuticals by 8.6% in the 1st quarter. Redmile Group LLC now owns 5,116,263 shares of the company’s stock valued at $210,637,000 after purchasing an additional 406,765 shares during the last quarter. Candriam Luxembourg S.C.A. raised its stake in Deciphera Pharmaceuticals by 1,797,864.3% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 251,715 shares of the company’s stock valued at $15,033,000 after purchasing an additional 251,701 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new position in Deciphera Pharmaceuticals in the 1st quarter valued at about $10,004,000. 74.63% of the stock is owned by institutional investors and hedge funds.

A number of analysts have issued reports on DCPH shares. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 29th. BidaskClub downgraded Deciphera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 7th. SunTrust Banks boosted their target price on Deciphera Pharmaceuticals from $82.00 to $91.00 and gave the company a “buy” rating in a report on Monday, May 18th. Guggenheim reissued a “buy” rating and issued a $70.00 target price on shares of Deciphera Pharmaceuticals in a report on Friday, June 12th. Finally, Barclays reissued a “buy” rating and issued a $85.00 target price (up from $80.00) on shares of Deciphera Pharmaceuticals in a report on Monday, May 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $70.57.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: What is a Tariff?

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.